Rheumatoid Arthritis Treatment - Small Molecules, Biologics, Therapy II

Session Type: ACR Abstract Submissions
Monday, November 7, 2011: 9:00 AM-6:00 PM
Hall F2 - Poster Hall (McCormick Place West)
Papers:
Treating to Target Matrix Metalloproteinase 3 Normalisation Together with Disease Activity Score Below 2.6 Yields Better Effects Than Each Alone In Rheumatoid Arthritis Patients: Treating to Twin Targets; T-4 Study
Yukitomo Urata1, Ryoko Uesato1, Dai Tanaka1, Yoshihide Nakamura2 and Shigeru Motomura2, 1Seihoku Chuo Hospital, Gosyogawara, Japan, 2Hirosaki University Graduate School of Medicine, Hirosaki, Japan
Risk of Infections In Rheumatoid Arthritis Patients Treated with Tocilizumab – a Retrospective Data-Analysis
Veronika Lang1, Matthias Englbrecht1, Jürgen Rech1, Bernhard Manger2, Georg Schett3 and Jochen Zwerina4, 1University of Erlangen-Nuremberg, Erlangen, Germany, 2Medical School Erlangen, Erlangen, Germany, 3Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, 4University of Erlangen-Nuremberg, Germany, Erlangen, Germany
Bone Resorption, OsteoClastogenesis and Adalimumab. A Study On the Impact of Anti-Tumor Necrosis Factor Therapy On Osteoclastogenesis In Patients with Rheumatoid Arthritis
Sabrina Guay-Belanger, Universite de Sherbrooke, Sherbrooke, QC and Arthur J. Fernandes, Universite de Sherbrooke, Sherbrooke
Golimumab’s Efficacy in Patients with Very Active Disease in Methotrexate-naïve Rheumatoid Arthritis
Paul Emery, Chapel Allerton Hospital, Leeds, United Kingdom, R. M. Fleischmann, University of Texas Southwestern Medical Center and Metroplex Clinical Research Center, Dallas, TX, Elizabeth C. Hsia, Centocor R&D, a division of Johnson & Johnson Pharmaceutical Research & Development, LLC, Malvern, PA, Stephen Xu, Centocor R & D, a division of Johnson & Johnson Pharmaceutical Research & Development, LLC, Weichun Xu, Centocor R&D, a division of Johnson & Johnson Pharmaceutical Research & Development, LLC, Malvern and Daniel G. Baker, Centocor R & D, a division of Johnson & Johnson Pharmaceutical Research and Development, LLC, Malvern, PA
Impact of Rituximab On the Quality of Life and Physical Function of Patients with Rheumatoid Arthritis: Results From the British Society for Rheumatology Biologics Register
Moetaza M. Soliman1, Kimme L. Hyrich2, Mark Lunt2, Kath D. Watson2, Deborah PM Symmons2 and Darren M. Ashcroft1, 1School of Pharmacy and Pharmaceutical sciences, University of Manchester, Manchester, United Kingdom, 2Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom
Mortality and Cause of Death In Young Rheumatoid Arthritis Patients Treated with Anti-TNF Therapy: Results From the British Society for Rheumatology Biologics Register
Malack Alachkar, Kath D. Watson, Kimme L. Hyrich and Deborah PM Symmons, Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom
Tofacitinib (CP-690,550), An Oral Janus Kinase Inhibitor, As Monotherapy in Patients with Active Rheumatoid Arthritis: A Comparison Between Japanese and Global Populations Over 12 Weeks of Dosing in Phase 2b Studies
T. Takeuchi1, Y. Tanaka2, H. Yamanaka3, M. Suzuki4, H. Nakamura4, K. Yazawa4, S. Toyoizumi4, J. D. Bradley5 and S. H. Zwillich5, 1Keio University School of Medicine, Tokyo, Japan, 2University of Occupational & Environmental Health, Kitakyushu, Fukuoka, Japan, 3Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, 4Pfizer Inc., Tokyo, Japan, 5Pfizer Inc., Groton, CT
Early Aggressive Intervention for Rheumatoid Arthritis Increases Rate of Remission Defined Using a Boolean Approach in Clinical Practice with Tocilizumab
Toshihisa Kojima1, Atsushi Kaneko2, Yuji Hirano3, Hisato Ishikawa4, Yuichiro Yabe5, Hideki Takagi6, Masatoshi Hayashi1, Koji Funahashi1, Daizo Kato1, Hiroyuki Matsubara7, Naoki Ishiguro8 and TBCR Study Group7, 1Nagoya Univeristy, School of Medicine, Nagoya, Japan, 2Nagoya Medical Center, Nagoya, Japan, 3Toyohashi Municipal Hospital, Toyohashi, Japan, 4Nagano Red Cross Hospital, Nagano, Japan, 5Tokyo Kosei Hospital, Tokyo, Japan, 6Nagoya Kyoritsu Hospital, Nagoya, Japan, 7Nagoya, Japan, 8Nagoya University, Graduate School & Faculty of Medicine, Nagoya, Aichi, Japan
Tofacitinib (CP-690,550), An Oral Janus Kinase Inhibitor, As Monotherapy or with Background Methotrexate in Japanese Patients with Rheumatoid Arthritis: A Phase 2/3 Long-Term Extension Study
H. Yamanaka1, Y. Tanaka2, T. Takeuchi3, M. Suzuki4, H. Nakamura4, Y. Komuro4, S. Toyoizumi4, J. D. Bradley5 and S. H. Zwillich5, 1Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, 2University of Occupational & Environmental Health, Kitakyushu, Fukuoka, Japan, 3Keio University School of Medicine, Tokyo, Japan, 4Pfizer Inc., Tokyo, Japan, 5Pfizer Inc., Groton, CT
Baseline Predictors of Remission with Combination Etanercept-Methotrexate Therapy in Moderately Active Rheumatoid Arthritis: Interim Results of the PRESERVE Trial
Josef Smolen1, Annette Szumski2, Lisa Marshall2 and Andrew S. Koenig2, 1Medical University of Vienna and Hietzing Hospital, Vienna, Austria, 2Pfizer Inc., Collegeville, PA
Is Long-Term Etanercept Monotherapy Ever An Option in a Patient with Moderate to Severe Rheumatoid Arthritis (RA)?
Roy M. Fleischmann, University of Texas Southwestern Medical Center and Metroplex Clinical Research Center, Dallas, TX, Michael H. Schiff, Rheumatology Division, University of Colorado, Denver, CO, Deborah Wenkert, Amgen, Thousand Oaks, CA, Bojena Bitman, Amgen Inc., South San Francisco, CA, Sandeep Chaudhari, KForce Clinical Research, Tampa, FL, Jie Liu, SimulStat Incorporated, San Diego, CA, Grace S. Park, Amgen Inc., Thousand Oaks, CA and Debra J. Zack, Amgen Inc, Thousand Oaks, CA
Efficacy and Safety of Certolizumab Pegol Plus Methotrexate in Japanese Rheumatoid Arthritis Patients with An Inadequate Response to Methotrexate
Kazuhiko Yamamoto, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan, Tsutomu Takeuchi, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan, Hisashi Yamanaka, Institute of Rheumatology, Tokyo Women's Medical University, Shinjuku-ku, Tokyo, Japan, Naoki Ishiguro, Nagoya University, Graduate School & Faculty of Medicine, Nagoya, Aichi, Japan, Yoshiya Tanaka, University of Occupational & Environmental Health, Kitakyushu, Fukuoka, Japan, Katsumi Eguchi, Sasebo City General Hospital, Sasebo, Nagasaki, Japan, Akira Watanabe, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Miyagi, Japan, Hideki Origasa, University of Toyama School of Medicine, Toyama, Toyama, Japan, Toshiharu Shoji, Otsuka Pharmaceutical Co., Ltd, Shinagawa-ku, Tokyo, Japan, Yoshiharu Sakamaki, UCB Inc, Chiyoda, Tokyo, Japan, Nobuyuki Miyasaka, Graduate School of Medicine and Dentistry, Tokyo Medical and Dental University, Bunkyo-ku, Tokyo, Japan and Takao Koike, Sapporo Medical Center NTT EC, Sapporo, Japan
Integrated Safety Summary of Modified-Release Prednisone and Immediate-Release Prednisone Comparing Doses ≤5mg/Day Versus >5mg/Day
Frank Buttgereit1, Jacek Szechinski2, Gisela Doering3, Stephan Witte4, Christine Knauer4, Amy Y. Grahn5, Kenneth G. Saag6 and Rieke Alten7, 1Charité University Medicine, Berlin, Germany, 2Wroclaw Medical University, Wroclaw, Poland, 3Merck KgaA, Darmstadt, Germany, 4Horizon Pharma GmbH, Mannheim, Germany, 5Horizon Pharma, Inc., Northbrook, IL, 6University of Alabama at Birmingham, Birmingham, AL, 7Rheumatology Schlossparkklinik, Berlin, Germany
Efficacy and Safety of Certolizumab Pegol without Methotrexate Co-Administration in Japanese Patients with Active Rheumatoid Arthritis
Kazuhiko Yamamoto, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan, Tsutomu Takeuchi, Keio University School of Medicine, Tokyo, Japan, Hisashi Yamanaka, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, Naoki Ishiguro, Nagoya University, Graduate School & Faculty of Medicine, Nagoya, Aichi, Japan, Yoshiya Tanaka, University of Occupational and Environmental Health, Japan, Kitakyushu, Fukuoka, Japan, Katsumi Eguchi, Sasebo City General Hospital, Sasebo, Nagasaki, Japan, Akira Watanabe, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Miyagi, Japan, Hideki Origasa, University of Toyama School of Medicine, Toyama, Toyama, Japan, Koichi Iwai, Otsuka Pharmaceutical Co., Ltd, Shinagawa-ku, Tokyo, Japan, Yoshiharu Sakamaki, UCB Inc, Chiyoda, Tokyo, Japan, Nobuyuki Miyasaka, Tokyo Medical and Dental University, Tokyo, Japan and Takao Koike, Sapporo Medical Center NTT EC, Sapporo, Japan
Dose Escalation Among Rheumatoid Arthritis Patients Treated with Infliximab or Abatacept: Comparison in Claims Data
Theodore Darkow1, Benjamin Chastek2, Lisa Rosenblatt1, Digisha Trivedi1, Tony Hebden1, Henry Henk2 and Fang Liu2, 1Bristol-Myers Squibb, Plainsboro, NJ, 2Innovus, an Optum Insight Company, Eden Prairie, MN
The Effectiveness of Abatacept in a Large Rheumatoid Arthritis Real World Practice:  Changes in the HAQ Over Time and Durability of Response
Janet E. Pope1, Emmanouil Rampakakis2, John S. Sampalis2 and Olivier Desjardins3, 1St. Joseph's Health Care, University of Western Ontario, London, ON, 2McGill University & JSS Medical Research, Montreal, QC, 3Bristol Myers Squibb Canada, St. Laurent, QC
Drug Survival and Long-Term Dose Comparison of Etanercept and Infliximab in Rheumatoid Arthritis Patients
Brian D. Hanna, McMaster University, Ontario, Kitchener, ON and Alpesh Shah, Community Rheumatology Clinic, Etobicoke, ON
Remission According to Different Composite Disease Activity Indices in Biologic-naïve Patients with Rheumatoid Arthritis Treated with Abatacept or Infliximab Plus Methotrexate
Josef S. Smolen1, Maxime Dougados2, Corine Gaillez3, Coralie Poncet4, Manuela Le Bars3, Monica Mody5 and Michael H. Schiff6, 1Medical University of Vienna and Hietzing Hospital, Vienna, Austria, 2Hôpital Cochin, Paris, France, 3Bristol-Myers Squibb, Rueil Malmaison, France, 4Docs International, Sévres, France, 5Bristol-Myers Squibb, Princeton, NJ, 6University of Colorado, Denver, CO
Pharmacokinetics of IV Abatacept in Systemic Lupus Erythematosus Patients with Active Proliferative Glomerulonephritis
Michael Tagen1, Blisse Vakkalagadda1, Neelima Thanneer1, Stephanie Meadows-Shropshire1, Martin Ullmann1, Robert Wong1, Richard Aranda2 and Bindu Murthy1, 1Bristol-Myers Squibb, Princeton, NJ, 2Bristol-Myers Squibb [at time of study], Princeton, NJ
Clinical Effect of Abatacept in Patients with Rheumatoid Arthritis, Data From the Swedish Rheumatology Quality Registry
Ralph Nisell1, Leszek Stawiarz2 and Staffan Lindblad1, 1Karolinska University Hospital, Stockholm, Sweden, 2Karolinska Institutet and Carmona AB, Stockholm / Halmstad, Sweden
Sustained Clinical Response with Golimumab Administered Subcutaneously Every 4 Weeks in Ankylosing Spondylitis: 104-Week Results of a Randomized, Placebo-Controlled Study
Jürgen Braun1, Desiree van der Heijde2, Atul Deodhar3, Anna Beutler4, Michael Mack4, Benjamin Hsu5 and Robert D. Inman6, 1Rheumazentrum Ruhrgebiet, Herne, Germany, 2Leiden University Medical Center, Leiden, Netherlands, 3Oregon Health & Science University, Portland, OR, 4Centocor R&D, a division of Johnson & Johnson Pharmaceutical Research & Development, LLC, Malvern, PA, 5Centocor R&D, a division of J&J Pharmaceutical R& D, LLC/Univ. of Pennsylvania, Malvern/Philadelphia, PA, 6Toronto Western Research Institute, University Health Network and University of Toronto, Toronto, ON
Fatigue and Morning Stiffness Are Correlated in Early Arthritis and Both Are Substantially Improved by Glucocorticoids
Gisela Westhoff, German Rheumatism Research Center Berlin, Berlin, Germany, Angela Zink, Deutsches Rheumaforschungszentrum and Charité University Medicine, Berlin, Germany and Frank Buttgereit, Charité University Medicine, Berlin, Germany
Different Remission Definitions Capture Different Proportions of patients with Rheumatoid Arthritis Treated in Clinical Practice
Till Uhlig1, Elisabeth Lie1, Cecillie Kaufmann2, Erik Rodevand3, Knut Mikkelsen4, Synnøve Kalstad5 and Tore K. Kvien1, 1Diakonhjemmet Hospital, Oslo, Norway, 2Buskerud Central Hospital, Drammen, Norway, 3St. Olav Hospital, Trondheim, Norway, 4Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway, 5University Hospital in Northern Norway, Tromsø, Norway
Patient-Reported Disease Activity Including Joint Assessment: A Comparison of RADAI (Rheumatoid Arthritis Disease Activity Index) and RAPID3 (Routine Assessment of Patient Index Data 3) in Patients Treated with Certolizumab Pegol Over 12 Weeks
Michael E. Weinblatt, Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, Janet E. Pope, St. Joseph's Health Care, University of Western Ontario, London, ON, Roy M. Fleischmann, MCRC, University of Texas, Dallas, TX, Clifton O. Bingham, Johns Hopkins University, Baltimore, MD, Geoffroy Coteur, UCB, Brussels, Belgium and Maxime Dougados, Paris-Descartes University, Cochin Hospital, Paris, France
Initial Combination Therapy with Adalimumab Plus Methotrexate Leads to Better Long-Term Outcomes Than with Either Monotherapy in Patients with Early Rheumatoid Arthritis: 8-Year Results of An Open-Label Extension of a Phase 3 Trial
Ferdinand C. Breedveld1, Edward Keystone2, Désirée van der Heijde3, Robert Landewe4, Josef Smolen5, Benoit Guerette6, Melissa McIlraith6, Hartmut Kupper7, Shufang Liu8, Benjamin Wolfe8 and Arthur Kavanaugh9, 1Leiden Univ Medical Ctr, Leiden, Netherlands, 2University of Toronto, Toronto, ON, 3Leiden University Medical Center, Leiden, Netherlands, 4Academic Medical Center, Amsterdam, Netherlands, 5Medical University of Vienna and Hietzing Hospital, Vienna, Austria, 6Abbott, Rungis, France, 7Abbott GmbH & Co KG, Ludwigshafen, Germany, 8Abbott, Abbott Park, IL, 9University of California San Diego, San Diego, CA
Association Between Leptin, Adiponectin and TNF-α and Response to Treatment in Patients with Rheumatoid Arthritis
Daniel X. Xibille Friedmann1, Sara Eugenia Hernandez Gongora2, Carolina Bustos Bahena3, Liliana Dominguez Hernandez3, Ivan Martinez Rivera3, Marisol Sandoval Rios3, Jorge Eduardo Ortiz Panozo4 and Jose Luis Montiel Hernandez5, 1Hospital General de Cuernavaca, Cuernavaca Morelos, Mexico, 2Postgraduate Research Coordination, School of Medicine, Universidad Latinoamericana, Cuernavaca, México, 3Cytokines and Autoimmunity Laboratory, Faculty of Pharmacy, Universidad Autónoma del Estado de Morelos, Cuernavaca, México, Cuernavaca, Mexico, 4Center for Population Health Research. Instituto Nacional de Salud Pública, Cuernavaca, México, 5Cytokines and Autoimmunity Laboratory, Faculty of Pharmacy, Universidad Autónoma del Estado de Morelos, Cuernavaca, México
Safety and Efficacy of Etanercept Over Five Years in a Large, UK Observational Cohort
C. D. Poole1, Paul Emery2, Adam Young3, Duncan Porter4, C. L. Morgan1, H. Walker5, C. J. Currie6 and A. Reynolds7, 1Pharmatelligence, Cardiff, United Kingdom, 2Chapel Allerton Hospital, Leeds, United Kingdom, 3City Hospital, St Albans, United Kingdom, 4Gartnavel General Hosp, Glasgow, United Kingdom, 5Pfizer UK Ltd, Tadworth, United Kingdom, 6Cardiff University, Cardiff, United Kingdom, 7Reynolds Clinical Sciences Ltd, Eastleigh, United Kingdom
Response with Combination Therapy - Methotrexate, Sulfasalazine, and Hydroxychloroquine - Appears Similar to the Response to Methotrexate and Anti-Tumor Necrosis Factor in US Veterans in the Veterans Affairs Rheumatoid Arthritis Registry
Grant W. Cannon1, Brian C. Sauer1, Candace L. Hayden1, Stephen G. Pickard1, Gail S. Kerr2, J. Steuart Richards2, Dannette S. Johnson3, Liron Caplan4, Ted R. Mikuls5 and Andreas M. Reimold6, 1Salt Lake City VA and University of Utah, Salt Lake City, UT, 2Washington DC VA and Georgetown University, Washington, DC, 3Jackson VA and University of Mississippi Medical Center, Jackson, MS, 4Denver VA and University of Colorado, Aurora, CO, 5Omaha VA and University of Nebraska, Omaha, NE, 6Dallas VA and University of Texas Southwestern, Dallas, TX
Greater Physical Dysfunction Is a Negative Predictor for Achieving Boolean-Based Remission in Patients with Rheumatoid Arthritis Treated with Tocilizumab
Daisuke Hoshi, Kumi Shidara, Yohei Seto, Eiichi Tanaka, Ayako Nakajima, Shigeki Momohara, Atsuo Taniguchi and Hisashi Yamanaka, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan
Direct Comparison of Four Biologics in Biologic-naïve Rheumatoid Arthritis Patients
Yukio Yonemoto1, Kimihiko Takeuchi2, Koichi Okamura1, Masatoshi Matsushita2, Tsutomu Kobayashi1, Tetsuo Aramaki2, Tetsuya Kaneko1 and Kenji Takagishi1, 1Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan, 2Isesaki Fukushima Hospital, Isesaki, Gunma, Japan
Impact of Tocilizumab Therapy for Remission Quartet in Rheumatoid Arthritis –the Result of 104 Weeks Follow up Data of REACTION study–
Yoshiya Tanaka1, Tsutomu Takeuchi2, Koichi Amano3, Eri Sato4, Masao Nawata5, Hayato Nagasawa6, Daisuke Hoshi7, Kazuyoshi Saito8, Shunsuke Fukuyo5, Kentaro Hanami8, Hideto Kameda2, Takahiko Kurasawa6, Yuko Kaneko9 and Hisashi Yamanaka4, 1University of Occupational and Environmental Health, Japan, Kitakyushu, Fukuoka, Japan, 2Keio University School of Medicine, Tokyo, Japan, 3Saitama Medical Center, Saitama Medical University, Saitama, Japan, 4Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, 5University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, 6Saitama Medical Ctr, Kawagoe, Japan, 7Tokyo Women's Medical University, Tokyo, Japan, 8University of Occupational & Environmental Health, Japan, Kitakyushu, Japan, 9Keio Univ School of Medicine, Shinjuku-ku, Japan
Clinical Response At Months 1–6 Can Predict Likelihood of Achieving Remission in Abatacept Plus Methotrexate-Treated Patients with Early Rheumatoid Arthritis
Yusuf Yazici, NYU Hospital for Joint Diseases, New York, NY, Jurgen Wollenhaupt, Schoen-Klinik Hamburg-Eilbek, Hamburg, Germany, Patrick Durez, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium, Juan J. Gomez-Reino, Hospital Clinico Universitario, Santiago de Compostela, Spain, Walter Grassi, Università Politecnica delle Marche, Ancona, Italy, Manuela Le Bars, Bristol-Myers Squibb, Rueil-Malmaison, France, Corine Gaillez, Bristol-Myers Squibb, Rueil Malmaison, France, Coralie Poncet, Docs International, Issy les Moulineaux, France, Ayanbola Elegbe, Bristol-Myers Squibb, Princeton, NJ and Rene Westhovens, UZ Gasthuisburg, Leuven, Belgium
Impact of Tocilizumab Therapy After Switching From Tumor Necrosis Factor (TNF) inhibitors – Prevention of Joint Damage by Tocilizumab in Patients with Inadequate Response to Anti-TNF Therapies –
Yoshiya Tanaka1, Tsutomu Takeuchi2, Koichi Amano3, Eri Sato4, Masao Nawata5, Hayato Nagasawa6, Daisuke Hoshi7, Kazuyoshi Saito8, Shunsuke Fukuyo5, Kentaro Hanami8, Hideto Kameda2, Takahiko Kurasawa6, Yuko Kaneko9 and Hisashi Yamanaka4, 1University of Occupational and Environmental Health, Japan, Kitakyushu, Fukuoka, Japan, 2Keio University School of Medicine, Tokyo, Japan, 3Saitama Medical Center, Saitama Medical University, Saitama, Japan, 4Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, 5University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, 6Saitama Medical Ctr, Kawagoe, Japan, 7Tokyo Women's Medical University, Tokyo, Japan, 8University of Occupational & Environmental Health, Japan, Kitakyushu, Japan, 9Keio Univ School of Medicine, Shinjuku-ku, Japan
Comparative Efficacy and Tolerability of Biologic Therapies in Early Rheumatoid Arthritis Utilizing a Bayesian Approach
Yusuf Yazici1, Christopher Swearingen2, Anagha Nadkarni3 and Lisa Rosenblatt3, 1Division of Rheumatology, New York University School of Medicine and NYU Hospital for Joint Diseases, New York, NY, 2University of Arkansas, Little Rock, AR, 3Bristol-Myers Squibb, Plainsboro, NJ
Differences in Gene Expression Profiles in Rheumatoid Arthritis Peripheral Blood Mononuclear Cells Suggest Apoptosis As Relevant Mechanism for Response to Methotrexate Monotherapy
RD Oliveira1, V. Fontana, C. Macedo, CM Junta, Eduardo A. Donadi3, GA Passos and Paulo Louzada-Junior1, 1School of Medicine of Ribeirao Preto - University of Sao Paulo, Ribeirao Preto, Brazil, 2Faculty Med of Ribeirao Preto, Ribeirao Preto, Brazil
Comorbidity and Cost Burden of Patients Prior to Initiating Abatacept or Infliximab As First Line Biologic Therapy for the Treatment of Rheumatoid Arthritis
Theodore Darkow, Digisha Trivedi, Brian Meissner, Lisa Rosenblatt and Tony Hebden, Bristol-Myers Squibb, Plainsboro, NJ
Fatigue in Patients with Rheumatoid Arthritis Treated with Tocilizumab (Actemra®) in Real Life: Clinically Relevant Improvement in 62% of Patients At 4 Months and Rapid Onset of Action. the PEPS Study
Laure Gossec, Cochin Hospital, Paris, France, Stephanie Rouanet, Roche, Neuilly sur Seine, France, Ghislaine Steinberg, Roche, Neuilly Sur Seine, France and Bernard G. Combe, Hopital Lapeyronie, Montpellier, France
Treatment Satisfaction and Adherence of Patients on Biologic Monotherapy
Jörg Kaufmann1, Anne-Eve Roske2, Adrian Kielhorn2, Eugen Feist3 and Wolfgang A. Schmidt4, 1Rheumatologist, Ludwigsfelde, Germany, 2Roche Pharma AG, Grenzach-Wyhlen, Germany, 3Charité Medical School, Berlin, Germany, 4Med Ctr Rheumatol Berlin Buch, Berlin, Germany
Baseline Tender Joint Count Scores Predict Long-Term Household Productivity in Patients with Rheumatoid Arthritis Treated with Certolizumab Pegol Plus Methotrexate
Arthur Kavanaugh, University of California San Diego, San Diego, CA, Oana Purcaru, UCB, Brussels, Belgium, Josef Smolen, Medical University of Vienna and Hietzing Hospital, Vienna, Austria, Paul Emery, Chapel Allerton Hospital, Leeds, United Kingdom, Vibeke Strand, Stanford University, Palo Alto, CA, Edward Keystone, University of Toronto, Toronto, ON and Ronald F. van Vollenhoven, Karolinska Institute, Stockholm, Sweden
Improvement & Maintenance of Hemoglobin Levels Among Rheumatoid Arthritis,Psoriatic Arthritis&Ankylosing Spondylitis Patients with Anemia of Inflammation After Treatment with Golimumab:3 Year Pooled Analysis
Daniel E. Furst, UCLA, Los Angeles, CA, Tim Gathany, Johnson & Johnson Pharmaceutical Services, LLC, Horsham, PA, Jonathan Kay, University of Massachusetts Memorial Medical Center/University of Massachusetts Medical School, Worcester, MA, Mary Chester Wasko, Temple University School of Medicine, Pittsburgh, PA, Edward Keystone, University of Toronto, Toronto, ON, Arthur Kavanaugh, University of California San Diego, San Diego, CA, Atul Deodhar, Oregon Health & Science University, Portland, OR, Frederick T. Murphy, Altoona Ctr for Clinical Research, Duncansville, PA, Chenglong Han, Johnson & Johnson Pharmaceutical Services, LLC, Malvern, PA and Mittie K. Doyle, Centocor R&D, a division of Johnson & Johnson Pharmaceutical Research & Development, LLC/University of Pennsylvania School of Medicine, Malvern/Philadelphia, PA
Rheumatologists’ Benefit-Risk Preferences for Biologic Treatments for Rheumatoid Arthritis
A. Brett Hauber1, James T. Cross2, David E. Yocum3, F. Reed Johnson1, Jui-Chen Yang1, Isidro Villaneuva2 and Patricia P. Katz4, 1RTI Health Solutions, Research Triangle Park, NC, 2Genentech, Inc., South SanFrancisco, CA, 3Genentech, Inc, South San Francisco, CA, 4University of California San Francisco, San Francisco, CA
Assessment of Immune Responses to Pneumococcal and Influenza Vaccines in Patients with Rheumatoid Arthritis Receiving Certolizumab Pegol
Alan J. Kivitz1, Joy Schechtman2, Michele Texter3, Andreas Fichtner4 and Elliot Chartash*3, 1Altoona Center for Clinical Research, Duncansville, PA, 2SunValley Arthritis Center, Peoria, AZ, 3UCB, Smyrna, GA, 4UCB Biosciences GmBH, Monheim, Germany
Number of Cardiovascular Risk Factors May be Associated with Higher Disease Activity Severity. Exploratory Analysis of Baseline Data from the Canadian Methotrexate and Etanercept Outcome Study: A Randomized Trial of Etanercept and Methotrexate vs Etanercept Alone in Rheumatoid Arthritis
Janet Pope, Univ of Western Ontario, London, ON, Edward Keystone, University of Toronto, Toronto, ON, Boulos Haraoui, Institut de Rhumatologie, Montreal, QC, J. Carter Thorne, Southlake Regional Health Centre, Newmarket, Newmarket, ON and Melanie Poulin-Costello, Amgen Canada Inc., Mississauga, ON
Effect on rheumatoid factor and anti-Cyclic Citrullinated Peptide Antibodies Levels of treatment with Infliximab and Adalimumab in patients with Rheumatoid Arthritis
Selene Baos, Chamaida Plasencia, Susana Ramiro, Rosario Moral, Jesús Díez, E. Martin-Mola, Alejandro Balsa and Dora Pascual-Salcedo, La Paz University Hospital, Madrid, Spain
Does Single Nucleotide Polymorphism in Folate Metabolic Pathway Contribute to Methotrexate Efficacy in Indian (Asian) Patients with Rheumatoid Arthritis?
Yogita Ghodke1, Arvind Chopra2, Amrutesh S. Puranik1, Pooja Shintre3, Anjali Radkar4, Kalpana Joshi5 and Bhushan Patwardhan5, 1University of Minnesota, Minneapolis, MN, 2Centre for Rheumatic Diseases, Pune 411001, India, 3Sinhgad College of Engineering, Pune, India, 4Gokhale Institute of Politics and Economics, Pune, India, 5Symbiosis International University, Pune - 411042, India
Association of ACR Clinical Responses with CDAI (Clinical Disease Activity Index) and RAPID3 (Routine Assessment of Patient Index Data 3) Indices of Disease Activity in Rheumatoid Arthritis Patients Treated with Certolizumab Pegol Plus Methotrexate
Michael H. Schiff1, Kristel Luijtens2, Owen Davies2 and Yusuf Yazici3, 1Rheumatology Division, University of Colorado, Denver, CO, 2UCB, Brussels, Belgium, 3Division of Rheumatology, New York University School of Medicine and NYU Hospital for Joint Diseases, New York, NY
Efficacy and Safety of Certolizumab Pegol in a Broad Population of Patients with Active Rheumatoid Arthritis: Week 28 Results From a Phase IIIb Randomized Controlled Study
Michael E. Weinblatt, Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, Roy M. Fleischmann, MCRC, University of Texas, Dallas, TX, Ronald F. van Vollenhoven, Karolinska Institute, Stockholm, Sweden, Paul Emery, Chapel Allerton Hospital, Leeds, United Kingdom, T.W.J. Huizinga, Leiden University Medical Centre, Leiden, Netherlands, Maurizio Cutolo, Research Laboratory and Academic Unit of Clinical Rheumatology, University of Genova, Genova, Italy, Ruth Goldermann, UCB, Monheim, Germany, Benjamin Duncan, UCB, Raleigh, NC, Owen Davies, UCB, Brussels, Belgium and Maxime Dougados, Rene Descartes University, Paris, France
No Change in Arterial Stiffness After 6 Months of Abatacept Treatment in Rheumatoid Arthritis
Sylvain Mathieu1, Bruno Pereira2, Emilie Rabois1, Anne Tournadre1, Jean Jacques Dubost1 and Martin Soubrier2, 1CHU Gabriel Montpied, Clermont-Ferrand, France, 2CHU CLERMONT-FERRAND, Clermont-Ferrand, France
Folate Metabolic Pathway Single Nucleotide Polymorphisms a Predictive Pharmacogenetic Marker of Methotrexate Related Adverse Events in Indian (Asian) Patients with Rheumatoid Arthritis
Yogita Ghodke1, Arvind Chopra2, Amrutesh S. Puranik1, Pooja Shintre3, Anjali Radkar4, Kalpana Joshi5 and Bhushan Patwardhan5, 1University of Minnesota, Minneapolis, MN, 2Centre for Rheumatic Diseases, Pune, India, 3Sinhgad College of Engineering, Pune, India, 4Gokhale Institute of Politics and Economics, Pune, India, 5Symbiosis International University, Pune - 411042, India
Design of a High Potency CTLA4-Ig with Extended Half-Life for Improved Dosing Convenience
Matthew J. Bernett, Seung Y. Chu, Holly M. Horton, Erik Pong, Irene Leung, Gregory L. Moore, Umesh S. Muchhal, Greg A. Lazar, David E. Szymkowski and John R. Desjarlais, Xencor, Inc., Monrovia, CA
Campylobacter Fetus Infection In Three Patients Treated with Rituximab for Rheumatoid Arthritis
Alain Meyer1, Arnaud Theulin2, Emmanuel Chatelus3, Christelle Sordet2, Rose-Marie Javier2, Helene Chifflot4, Jacques-Eric Gottenberg5 and Jean Sibilia6, 1Hautepierre Strasbourg university, Strasbourg, France, 2Hautepierre Strasbourg Hospital University, Strasbourg, France, 3Hopital Hautepierre, Strasbourg, France, 4Hautepierre Strasbourg Hospital University, 67000, France, 5Strasbourg University Hospital, Strasbourg, France, 6Service de rhumatologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France, Strasbourg, France
Short- and Long-Term Effect of Unguided, Intra-Articular Injections with Betamethasone In Early Rheumatoid Arthritis. Impact of Joint Area, Repeated Injections, MRI Findings, Anti-CCP, IgM-RF and CRP
Merete L. Hetland1, Mikkel Østergaard2, Bo J. Ejbjerg3, Søren Jacobsen4, Kristian Stengaard-Pedersen5, Peter Junker6, Tine Lottenburger6, Ib Hansen7, Lis Smedegaard Andersen8, Ulrik Tarp9, Anders Svendsen10, Jens Kristian Pedersen6, Henrik Skjødt11, Torkell Ellingsen12, Hanne M. Lindegaard6 and Kim Hørslev-Petersen13, 1Copenhagen University Hospital at Glostrup, on behalf of DANBIO, Copenhagen, Denmark, 2Copenhagen University Hospital in Glostrup, Glostrup, Denmark, 3Hospital at Slagelse, Slagelse, Denmark, 4Copenhagen University Hospital, Copenhagen, Denmark, 5Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, 6Odense University Hospital, Odense C, Denmark, 7Viborg Hospital, Viborg, Denmark, 8Denmark, 9Aarhus University Hospital, Aarhus, Denmark, 10Odense, Denmark, 11Copenhagen University Hospital at Glostrup, Copenhagen, Denmark, 12University Hospital, Silkeborg, Denmark, 13University of Southern Denmark, Graasten, Denmark
Pharmacokinetic-Pharmacodynamic Modeling of Ozoralizumab (ATN-103), a Novel Humanized Nanobody Tumor Necrosis Factor Inhibitor for Rheumatoid Arthritis
Chandrasekhar Udata1, Arnab Mukherjee2, Matt Hutmacher3, Mark Peterson1, Kai-Hsin Liao1, Tina Checchio2, Kathy Shields4, Xu Meng1 and Gail Comer4, 1Pfizer, San Diego, CA, 2Pfizer, Groton, CT, 3A2PG, Ann Arbor, MI, 4Pfizer, Collegeville, PA
Correlation of CDAI and SDAI with DAS in a Large Real-Life Cohort of Rheumatoid Arthritis Patients Treated with Infliximab
Denis Choquette, University of Montreal, Notre-dame Hospital, Montreal, QC, William G. Bensen, McMaster University, Hamilton, ON, Hamilton, ON, Milton F. Baker, VIHA, Victoria, BC, Sophie Elise Michaud, Merck Canada Inc, Montreal, QC and Hayssam Khalil, Merck Canada Inc, Kirkland, QC
Development of a Whole Blood Assay to Determine Rituximab Mediated Complement Dependent Cytotoxicity of B Lymphocytes
Jonathan D. Jones, Dartmouth-Hitchcock Medical Center, Lebanon, NH, B. JoNell Hamilton, Dartmouth College, Lebanon, NH, Whitney Hilton, Dartmouth Hitchcock Med Ctr, Lebanon, NH and William F. C. Rigby, Dartmouth-Hitchcock Med Ctr, Lebanon, NH
A Profile of Rheumatoid Arthritis Patients Treated with Tocilizumab in a United States Registry Population
Dimitrios A. Pappas1, Alan Rathbun2, George Reed3, Joel M. Kremer4, Isidro Villanueva5, Jenny Devenport6, Sarika Ogale6, Ani John6 and Jeffrey D. Greenberg7, 1Columbia University, College of Physicians & Surge, New York, NY, 2UMASS Medical School, Worcester, MA, 3UMass Medical School, Worcester, MA, 4Albany Medical College and The Center for Rheumatology, Albany, NY, 5Viregen Macarena Hospital, Sevilla, Spain, 6Genentech, South San Francisco, CA, 7New York University School of Medicine, New York, NY
SNP Algorithms for Prediction of Efficacy and Adverse Events of Abatacept
Tsukasa Matsubara1, Satoru Koyano2, Keiko Funahashi2, Takafumi Hagiwara1, Takako Miura1, Kosuke Okuda1, Takeshi Nakamura1, Mitsuyoshi Iwahashi3, Tomomi Tsuru4, Shoichi Uchimura5 and Shigeru Honjo6, 1Matsubara Mayflower Hospital, Kato, Japan, 2Research Institute of Joint Diseases, Kobe, Japan, 3Higashi-Hiroshima Memorial Hospital, Higashi-hiroshima, Japan, 4PS Clinic, Fukuoka, Japan, 5Kanzaki Municipal General Hospital, Kanzaki, Japan, 6Honjo Rheumatism Clinic, Takaoka, Japan
Low Persistence of Methotrexate Monotherapy in the Veterans Affairs Rheumatoid Arthritis (VARA) Registry
Grant W. Cannon1, Brian C. Sauer1, Katherine L. Martin1, Candace L. Hayden1, Andreas M. Reimold2, Liron Caplan3, J. Steuart Richards4, Gail S. Kerr4, Dannette S. Johnson5 and Ted R. Mikuls6, 1Salt Lake City VA and University of Utah, Salt Lake City, UT, 2Dallas VA and University of Texas Southwestern, Dallas, TX, 3Denver VA and University of Colorado, Aurora, CO, 4Washington DC VA and Georgetown University, Washington, DC, 5Jackson VA and University of Mississippi Medical Center, Jackson, MS, 6Omaha VA and University of Nebraska, Omaha, NE
Effects of TNF-Alpha Inhibitors on Lipid Profile and on Sub-Clinical Atherosclerosis in Rheumatoid Arthritis. Systematic Review and Meta-Analysis
Sylvain Mathieu1, Sarah Payet1, Bruno Pereira2, Eric Bruckert3 and Martin Soubrier2, 1CHU Gabriel Montpied, Clermont-Ferrand, France, 2CHU CLERMONT-FERRAND, Clermont-Ferrand, France, 3CHU Pitié-Salpêtrière, AP–HP, Paris
Evaluation of A Novel Homogeneous Mobility Shift Assay for the Measurement of Human Antibodies-to-Infliximab and Infliximab Levels in Patient Serum
Shui Long Wang, Linda Ohrmund, Scott Hauenstein, Jared Salbato, Rukmini Reddy, Patrick Monk, Steven Lockton, Nicholas Ling and Sharat Singh, Prometheus Laboratories, San Diego, CA
Tofacitinib Reduces Interferon-γ and Interleukin-17 Production From CD4+ T Cells in Patients with Rheumatoid Arthritis
Satoshi Kubo, Kunihiro Yamaoka, Koshiro Sonomoto, Keisuke Maeshima, Shintaro Hirata, Kazuhisa Nakano, Norifumi Sawamukai, Masao Nawata, Shigeru Iwata, Kazuyoshi Saito and Yoshiya Tanaka, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple, Intravenous, Ascending-Dose Study of Sirukumab in Patients with Cutaneous or Systemic Lupus Erythematosus
Jacek C. Szepietowski1, Surasak Nilganuwong2, Anna Wozniacka3, Annegret Kuhn4, Filippa Nyberg5, Jacek Szechinski1, Ronald F. van Vollenhoven6, Anders Bengtsson7, Adam Reich1, Dick de Vries8, Bart van Hartingsveldt8, Bei Zhou9 and Benjamin Hsu10, 1Wroclaw Medical University, Wroclaw, Poland, 2Siriraj Hospital, Bangkok, Thailand, 3Medical University of Lodz, Lodz, Poland, 4University of Münster, Münster, Germany, 5Karolinska Institutet, Danderyd Hospital, Stockholm, Sweden, 6Karolinska Institute, Stockholm, Sweden, 7Department of Rheumatology, Lund University Hospital, Sweden, 8Janssen Biologics B.V., Leiden, Netherlands, 9Centocor Research & Development, a Division of Johnson & Johnson Pharmaceutical Research & Development, LLC, Malvern, PA, 10Centocor R&D, a division of J&J Pharmaceutical R& D, LLC/Univ. of Pennsylvania, Malvern/Philadelphia, PA
Meta-Analysis Suggests Intensive Non-Biologic Combination Therapy with Step-Down Prednisolone May Also  ‘Disconnect’ Disease Activity and Damage in Rheumatoid Arthritis
Maarten Boers1, Lilian H.D. van Tuyl1, Marianne van den Broek2, Piet J. Kostense1 and Cornelia F. Allaart2, 1VU University Medical Center, Amsterdam, Netherlands, 2Leiden University Medical Center, Leiden, Netherlands
Clinical Response and B Cell Analysis by High-Sensitive Flowcytometry After the Second Course of Rituximab
Hans-Peter Brezinschek1, Franz Rainer2, Kerstin Brickmann1, Raimund Lunzer2 and Winfried B. Graninger1, 1Medical University Graz, Graz, Austria, 2Hospital Barmherzige Brueder, Graz- Eggenberg, Austria
Comparison of Tocilizumab and TNF Inhibitor Therapy in Rheumatoid Arthritis
Jörg Kaufmann, Rheumatologist, Ludwigsfelde, Germany, Susanne Seel, Ambulant Centres f. Rheumatology, Ludwigsfelde, Germany and Anne-Eve Roske, Roche Pharma AG, Grenzach-Wyhlen, Germany
Efficacy Evaluation of Tocilizumab with the New ACR/EULAR Remission Criteria and DAS28-ESR
Tomonori Ishii, Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan, Yasuhiko Hirabayashi, Hikarigaoka Spellman Hospital, Sendai, Japan and Michinoku Tocilizumab Study Group, Senndai
High Levels of Serum IL-6 but Not CRP or TNF-α During Tocilizumab Treatment Induces Myalgia Among the Patients with Rheumatoid Arthritis
Osamu Saiki, Shiraishi Hospital, Imabari, Japan and Hiroshi Uda, Keiseikai Hospital, Higashiosaka, Japan
Development of a Novel Recombinant Biotherapeutic with Applications in Targeted Therapy of Human Arthritis
Panagiotis Kamperidis1, Tahereh Kamalati1, Mathieu Ferrari1, Lewis Lee1, Rita Jones1, Toby Garrood1, Malcolm D. Smith2, Soraya Diez-Posada1, Chris Hughes1, Ciara Finucane1, Stephen Mather1, Ahuva Nissim1, Andrew J. T. George1 and Costantino Pitzalis3, 1London, United Kingdom, 2Adelaide, Australia, 3Centre for Experimental Medicine and Rheumatology, QMUL, London, United Kingdom
Gene Expression Profiling of Folate Pathway Related Genes in Methotrexate naïve- and Methotrexate-Treated Rheumatoid Arthritis Patients
Marjolein Blits1, Gerrit Jansen1, Yehuda G. Assaraf2 and Cornelis L. Verweij1, 1VU University Medical Center, Amsterdam, Netherlands, 2Technion, Haifa, Israel
Retrospective Analysis of the Efficacy of Tacrolimus in Rheumatoid Arthritis : Suggestive Synergistic Effects with Methotrexate
Kenta Hoshi, Sumiaki Tanaka, Tatsuhiko Wada, Junichi Tanaka, Tatsuo Nagai and Shunsei Hirohata, Kitasato University School of Medicine, Sagamihara, Japan
 Anti-CCP Titers Are Predictive of the Response to Biological Agents in Patients with Rheumatoid Arthritis
Ryo Takahashi1, Ryo Yanai1, Hidekazu Furuya1, Kuninobu Wakabayashi1, Tsuyoshi Odai1, Takeo Isozaki2, Nobuyuki Yajima1, Yusuke Miwa3 and Tsuyoshi Kasama1, 1Showa University School of Med, Shinagawa-ku Tokyo, Japan, 2University of Michigan Medical School, Ann Arbor, MI, 3Division of Rheumatology, Tokto, Japan
Abatacept Reduces N-Terminal Pro Brain Natriuretic Peptide Levels in Patients with Rheumatoid Arthritis: Results From a Prospective Cohort Study
Inge A.M. van den Oever, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands and Michael T. Nurmohamed, Reade, Centre for Rehabilitation and Rheumatology, Amsterdam, Netherlands
Do Impared Memory, Cognitive Dysfonction and Distress Play a Role In Methotrexate-Related Pancytopenia In Rheumatoid Arthritis Patients?
Salim Donmez1, Yavuz Pehlivan2, Omer Nuri Pamuk1, Bunyamin Kisacik2, Gulsum Emel Pamuk1, Ahmet Mesut Onat2, Mehmet Sayarlioglu3 and Gözde Yildirim Çetin3, 1Edirne, Turkey, 2Gaziantep, Turkey, 3Kahramanmaras, Turkey
Acute Pain Relief by a Proprietary, Nano-Formulated Lower-Dose Oral Indomethacin
Roy D. Altman, UCLA, Los Angeles, CA, Stephen Daniels, Premier Research Group, Austin, TX and Garen Manvelian, Iroko Pharmaceuticals, Poway, CA
A Phase 2 Study Evaluating the Acute Pain Relief of a Nano-Formulated Oral Naproxen
Garen Manvelian, Iroko Pharmaceuticals, Poway, CA, Stephen Daniels, Premier Research Group, Austin, TX, Allan Gibofsky, Hospital for Special Surgery, New York, NY and Vibeke Strand, Stanford University, Palo Alto, CA
Application of Nanotechnology to Improve Non-Steroidal Anti-Inflammatory Drugs
Garen Manvelian, Iroko Pharmaceuticals, Poway, CA, Roy D. Altman, UCLA, Los Angeles, CA and Vibeke Strand, Stanford University, Palo Alto, CA
Demonstration of the Symptomatic and Structural Effect of Methotrexate in Daily Practice As the First RA-DMARD Despite Its Sub-Optimal Use: Results From the ESPOIR Early Synovitis Cohort
Cécile Gaujoux-Viala, Paris 6 – Pierre et Marie Curie University; Rheumatology, Pitié-Salpêtrière Hospital, Paris, France, Simon Paternotte, Hopital Cochin, Paris, France, Bernard G. Combe, Hopital Lapeyronie, Montpellier, France and Maxime Dougados, Paris-Descartes University, Paris, France
See more of: ACR Abstract Submissions

To see other sessions for this day, use the date buttons to the left.